Ulrik Mouritzen

Immunology and Microbiology · Life Sciences

16h-index1.2kcitations32works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(8), Diabetes Treatment and Management(7), Diabetes Management and Research(7), CAR-T cell therapy research(7), Immune Cell Function and Interaction(5)

Publications32 total

Data from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Data from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Supplementary Figures S1-S3 from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Supplementary Figures S1-S3 from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes
International Journal of Molecular Sciences·2022· 16 citedOpen Access
Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
International Journal of Molecular Sciences·2021· 11 citedOpen Access
286-OR: Phase 3 Results for Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia
Diabetes·2019· 2 cited
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial
˜The œLancet. Gastroenterology & hepatology·2019· 75 cited
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
Diabetes Obesity and Metabolism·2018· 27 citedOpen Access
Low Doses of Dasiglucagon Consistently Increase Plasma Glucose (PG) Levels in Hypoglycemia and Euglycemia in People with Type 1 Diabetes Mellitus (T1DM)
Diabetes·2018
Inhibition of Cx43 gap junction uncoupling prevents high glucose-induced apoptosis and reduces excess cell monolayer permeability in retinal vascular endothelial cells
Experimental Eye Research·2018· 34 cited
Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial
Heart·2018· 28 citedOpen Access
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
Diabetes Care·2017· 108 cited
Administration of a gap junction coupler reduces retinal vascular cell loss associated with diabetic retinopathy
Investigative Ophthalmology & Visual Science·2017· 1 citedOpen Access
Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis
Journal of Hepatology·2017· 3 cited
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial
International Journal of Clinical Pharmacology and Therapeutics·2016· 43 cited
A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)
Acta Oncologica·2010· 39 citedOpen Access
Ultrasound-Guided Fine-Needle aspiration cytology (USFNAC) to detect melanoma cells in the sentinel node facilitates local administration of medication, here IL-21 (rIL21) in a novel neoadjuvant setting into the sentinel node of stage III Melanoma Patients
2010
Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
Clinical Cancer Research·2010· 56 cited
Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes
Diabetes Obesity and Metabolism·2009· 6 cited
page 1 of 2Next →

Frequent Co-authors

Birte K. Skrumsager(10), Ian D. Davis(9), Grant A. McArthur(9), Paul E.G. Kristjansen(8), Lasse Tengbjerg Hansen(7), Kresten Skak(7), Dorthe Lundsgaard(7), Klaus Stensgaard Frederiksen(7), Michael Millward(5), Jonathan Cebon(5), Ben Brady(4), Richard F. Kefford(4), Claus Christiansen(3), Ulrike Hövelmann(3), Daniela Lamers(3), Birgit Kronshage(3), Tim Heise(3), Ben Brady(2), Richard Kefford(2), Stephan Christgau(2)